Biomarker Analysis Contextualizes RFS Benefit With Nivolumab in Metastatic Melanoma
Source: OncLive, September 2023
Brian Gastman MD, discusses how findings from CheckMate76K contributed to the rationale for a biomarker analysis in that trial’s patient population, key findings from this biomarker analysis, and how these findings may inform further research regarding the benefits of immunotherapy in earlier-stage disease.
The first comprehensive biomarker analysis conducted in patients with stage IIB or IIC melanoma who received adjuvant nivolumab (Opdivo) demonstrates predictors of relapse-free survival (RFS) benefit in this population, according to Brian Gastman MD.
The phase 3 CheckMate76K trial (NCT04099251) randomly assigned patients with resected stage IIB or IIC melanoma with wide local excision and negative sentinel lymph node biopsy 2:1 to receive either nivolumab or placebo for 12 months. At a median follow-up of 15.8 months in the nivolumab arm and 15.9 months in the placebo arm, the median RFS was not reached ([NR]; 95% CI, 28.5 months to not assessed [NA]) with nivolumab (n = 526) vs NR (95% CI, 21.6 months-NA) with placebo (n = 264; HR, 0.42; 95% CI, 0.30-0.59; log-rank P < .0001).1,2